Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, has made available the replay of its Nasdaq Closing Bell Ceremony from August 8, 2025. The ceremony celebrated a significant milestone: the FDA 510(k) clearance for the company's new Daxor BVA鈩� (Blood Volume Analyzer).
The next-generation device is characterized as a patent-pending, rapid, compact, and hand-held blood volume measurement system designed for lab-based use.
Daxor Corporation (NASDAQ: DXR) ha reso disponibile la registrazione della cerimonia di chiusura del Nasdaq dell'8 agosto 2025. La cerimonia ha celebrato un traguardo importante: l'autorizzazione 510(k) della FDA per il nuovo Daxor BVA鈩� (Analizzatore del Volume Sanguigno) dell'azienda.
Il dispositivo di nuova generazione 猫 un sistema di misurazione del volume sanguigno con domanda di brevetto in corso, rapido, compatto e portatile, progettato per l'uso in laboratorio.
Daxor Corporation (NASDAQ: DXR) ha puesto a disposici贸n la grabaci贸n de su ceremonia de toque de campana de cierre en Nasdaq del 8 de agosto de 2025. La ceremonia celebr贸 un hito importante: la autorizaci贸n 510(k) de la FDA para el nuevo Daxor BVA鈩� (Analizador de Volumen Sangu铆neo) de la compa帽铆a.
El dispositivo de nueva generaci贸n es un sistema de medici贸n del volumen sangu铆neo pendiente de patente, r谩pido, compacto y de mano, dise帽ado para su uso en laboratorio.
Daxor Corporation (NASDAQ: DXR)電� 2025雲� 8鞗� 8鞚� 鞐措Π 雮橃姢雼� 韽愳灔 膦呾唽毽� 頄夓偓 雲鬼檾 鞓侅儊鞚� 瓿店皽頄堨姷雼堧嫟. 鞚� 頄夓偓電� 須岇偓鞚� 鞁犾牅頀� Daxor BVA鈩� (順堨暋霟� 攵勳劃旮�)鞐� 雽�頃� 欷戩殧頃� 鞚挫爼響滌澑 FDA 510(k) 項堦皜毳� 旮半厫頄堨姷雼堧嫟.
鞚� 彀劯雽� 旮瓣赴電� 鞐瓣惮鞁れ毄鞙茧 靹り硠霅� 順堨暋霟� 旄§爼 鞁滌姢韰滌溂搿�, 韸鬼棃 於滌洂 欷戩澊氅� 牍犽ゴ瓿� 靻岉槙鞐� 頊措寑 臧�電ロ暅 韸轨鞚� 臧栰稊瓿� 鞛堨姷雼堧嫟.
Daxor Corporation (NASDAQ: DXR) a rendu disponible la rediffusion de sa c茅r茅monie de cl么ture du Nasdaq du 8 ao没t 2025. La c茅r茅monie a c茅l茅br茅 une 茅tape importante : l'autorisation 510(k) de la FDA pour le nouveau Daxor BVA鈩� (Analyseur de volume sanguin) de l'entreprise.
Ce dispositif de nouvelle g茅n茅ration est un syst猫me de mesure du volume sanguin en instance de brevet, rapide, compact et portable, con莽u pour une utilisation en laboratoire.
Daxor Corporation (NASDAQ: DXR) hat die Aufzeichnung seiner Nasdaq-Schlussglocken-Zeremonie vom 8. August 2025 ver枚ffentlicht. Die Zeremonie w眉rdigte einen bedeutenden Meilenstein: die FDA-510(k)-Zulassung f眉r das neue Daxor BVA鈩� (Blutvolumen-Analysator) des Unternehmens.
Das Ger盲t der n盲chsten Generation ist ein System zur Messung des Blutvolumens, mit anh盲ngiger Patentanmeldung, schnell, kompakt und handlich, das f眉r den Laboreinsatz konzipiert wurde.
- Received FDA 510(k) clearance for next-generation Daxor BVA鈩�
- Successfully developed a compact, hand-held version of their blood volume measurement technology
- None.
The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA鈩�.
Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Daxor BVA鈩� (Blood Volume Analyzer).
You can watch the full replay of the event here: .
For more information, visit .
Sign up to receive news on Daxor鈥檚 innovative technology.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Investor Relations Contact:
Bret Shapiro
COO 鈥� Head of Capital Markets
COREIR
(561)-479-8566-Cell
|
FAQ
What milestone did Daxor (NASDAQ: DXR) celebrate at the Nasdaq Closing Bell Ceremony?
When did Daxor (DXR) ring the Nasdaq Closing Bell?
What are the key features of Daxor's new Blood Volume Analyzer?
Where can investors watch Daxor's Nasdaq Closing Bell Ceremony?
